Haptoglobin polymorphism and peripheral arterial occlusive disease

被引:60
|
作者
Delanghe, J
Langlois, M
Duprez, D
De Buyzere, M
Clement, D
机构
[1] State Univ Ghent Hosp, Dept Clin Chem, B-9000 Ghent, Belgium
[2] Belgian Natl Fund Sci Res, Flanders, Belgium
[3] State Univ Ghent Hosp, Dept Cardiol, B-9000 Ghent, Belgium
关键词
peripheral arterial occlusive disease; atherosclerosis; haptoglobin polymorphism; treadmill testing; angiogenesis;
D O I
10.1016/S0021-9150(99)00079-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haptoglobin (Hp) 2-2 phenotype is a genetic risk factor in coronary atherosclerosis. In this study, haptoglobin phenotypes were determined in 141 patients with peripheral arterial occlusive disease (PAOD) and compared to a reference population (n = 1000). The relative Hpl allele frequency was decreased among PAOD patients (0.294 vs. 0.403 for the reference population, P < 0.01) due to an overrepresentation of the Hp 2-2 phenotype (50%, odds ratio 1.82(95% C.I. 1.28-2.60), P < 0.001). This finding was even more pronounced in non-diabetic and in non-smoking PAOD patients (Hpl allele frequencies: 0.265 and 0.228, respectively). Serum lipids, inflammatory parameters, and blood pressure levels were comparable among the Hp phenotypes, but serum levels of the antioxidant vitamin C were lower in Hp 2-2 patients than in patients with another phenotype (P < 0.05). In PAOD patients with severe atherosclerotic lesions, maximal walking distance of patients carrying a Hp 2-2 phenotype (225-525 m) exceeded that of other Hp phenotypes (50-242 m) (interquartile ranges) (P < 0.05). The findings demonstrate that, despite an increased risk for developing PAOD, the Hp 2-2 phenotype is associated with a longer maximal walking distance which might be attributed to the earlier reported in vitro angiogenic properties of the Hp 2-2 molecule. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:287 / 292
页数:6
相关论文
共 50 条
  • [1] Haptoglobin polymorphism and peripheral arterial occlusive disease
    Langlois, M
    Delanghe, J
    Duprez, D
    DeBuyzere, M
    Bernard, D
    [J]. ATHEROSCLEROSIS, 1997, 130 : 107 - 107
  • [2] Haptoglobin polymorphism and peripheral arterial occlusive disease
    Langlois, H
    Delanghe, J
    Duprez, D
    De Buyzere, M
    Bernard, D
    Clement, DL
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 31 (02) : 499A - 499A
  • [3] Relationship between MTHFR gene polymorphism and peripheral arterial occlusive disease
    Liu, JW
    Liu, J
    Ye, L
    Li, XY
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 304 - 304
  • [4] PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
    SCHOOP, W
    [J]. HERZ KREISLAUF, 1985, 17 (04): : 167 - 170
  • [5] Peripheral arterial occlusive disease
    Tepohe, G
    [J]. ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 1999, 32 (02): : 297 - 297
  • [6] Peripheral arterial occlusive disease
    Minar, Erich
    [J]. VASA-JOURNAL OF VASCULAR DISEASES, 2007, 36 (03): : 155 - 164
  • [7] Peripheral arterial occlusive disease (pAOD)
    Karrer, S.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2009, 7 : 71 - 71
  • [8] Screening for peripheral occlusive arterial disease
    Diehm, C.
    Lawall, H.
    Pittrow, D.
    [J]. GEFASSCHIRURGIE, 2009, 14 (05): : 370 - +
  • [9] Garlic for peripheral arterial occlusive disease
    Jepson, Ruth G.
    Kleijnen, Jos
    Leng, Gillian C.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (04):
  • [10] Acute peripheral arterial occlusive disease
    Schumann, Romy
    Rieger, Johannes
    Ludwig, Malte
    [J]. MEDIZINISCHE KLINIK, 2007, 102 (06) : 457 - 471